Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 3M Company (MMM) vs Smith & Nephew plc (SNN) Price & Performance

3M CompanyTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

3M Company vs Smith & Nephew plc — how do they compare? 3M Company trades at $161.99 (market cap $84.36B), while Smith & Nephew plc trades at $27.29 (market cap $11.10B). The key difference: 3M Company is far larger — about 7.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Smith & Nephew plc for 120 Days on average.

MMMSNN
Market Cap
$84.36B$11.10B
Volume
2,325,3011,051,703
Sector
IndustrialsHealth
52-Week High
$183.79$37.17
52-Week Low
$141.10$26.42
Typical Hold Time
169 Days120 Days
Enterprise Value
$93.58B$14.13B
Dividend Yield
1.91%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

3M Company

3M (MMM) trades at $162.12, down 0.93% on the day, with a bearish technical signal and support near $158. The company reported strong Q2 2026 earnings, beating estimates with 5.4% organic growth and a 24.9% adjusted operating margin. Revenue for 2025 was $24.95B with net income of $3.25B, though margins have compressed from prior years. Analysts are mixed with a consensus price target of $191, representing potential upside, but high debt and weak consumer sales pose challenges.

The outlook for MMM is cautiously optimistic amid a genuine turnaround narrative. Investment opportunities include continued operational execution, shareholder returns via dividends and buybacks, and growth in industrial and electronics segments. Key risks involve persistent consumer segment weakness, litigation overhang from PFAS, and macroeconomic pressures affecting demand. The stock's valuation remains elevated with a P/E of 29.06, requiring sustained earnings growth to justify further gains.

Smith & Nephew plc

SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.

The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MMM
100% Buy0% Sell
Avg holding period · 169 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

Read more on MMM →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →